More articles from Myeloproliferative Disorders

Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis
Frederike Kramer, Jens Dernedde, Artur Mezheyeuski, Rudolf Tauber, Patrick Micke, Kai Kappert

Haematologica Oct 2019, haematol.2019.226332; DOI: 10.3324/haematol.2019.226332
Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms
Gaurav Goyal, Aishwarya Ravindran, Yuanhang Liu, Rong He, Mithun V. Shah, N. Nora Bennani, Mrinal M. Patnaik, Karen L. Rech, Ronald S. Go, Mayo Clinic Hisiocytosis Working Group

Haematologica Oct 2019, haematol.2019.234187; DOI: 10.3324/haematol.2019.234187
Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with Increased blasts (<10%) or with other types of disease progression
Julia T. Geyer, Elizabeth Margolskee, Spencer A. Krichevsky, Daniele Cattaneo, Leonardo Boiocchi, Paola Ronchi, Francesca Lunghi, Joseph M. Scandura, Maurilio Ponzoni, Robert P. Hasserjian, Umberto Gianelli, Alessandra Iurlo, Attilio Orazi

Haematologica Sep 2019, haematol.2019.230193; DOI: 10.3324/haematol.2019.230193
Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells
Koji Takaishi, Masahiro Takeuchi, Shokichi Tsukamoto, Naoya Takayama, Motohiko Oshima, Kenji Kimura, Yusuke Isshiki, Kensuke Kayamori, Yutaro Hino, Nagisa Oshima-Hasegawa, Shio Mitsukawa, Yusuke Takeda, Naoya Mimura, Chikako Ohwada, Tohru Iseki, Sou Nakamura, Koji Eto, Atsushi Iwama, Koutaro Yokote, Chiaki Nakaseko, Emiko Sakaida

Haematologica Sep 2019, haematol.2018.214841; DOI: 10.3324/haematol.2018.214841
Oncogenic fusion protein BCR-FGFR1 requires BCR-mediated oligomerization and chaperonin Hsp90 for activation
Malalage N. Peiris, April N. Meyer, Katelyn N. Nelson, Ezra W. Bisom-Rapp, Daniel J. Donoghue

Haematologica Aug 2019, haematol.2019.220871; DOI: 10.3324/haematol.2019.220871
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms
Kaitlyn Shank, Andrew Dunbar, Priya Koppikar, Maria Kleppe, Julie Teruya-Feldstein, Isabelle Csete, Neha Bhagwat, Matthew Keller, Outi Kilpivaara, Franziska Michor, Ross L. Levine, Laura de Vargas Roditi

Haematologica Aug 2019, haematol.2018.203729; DOI: 10.3324/haematol.2018.203729
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.
Nabih Maslah, Juliette Soret, Christine Dosquet, Laetitia Vercellino, Célia Belkhodja, Marie-Hélène Schlageter, Bruno Cassinat, Jean-Jacques Kiladjian, Christine Chomienne, Stephane Giraudier

Haematologica Aug 2019, haematol.2018.215582; DOI: 10.3324/haematol.2018.215582
Deletion of miR-451 curbs JAK2(V617F)-induced erythrocytosis in polycythemia vera by oxidative stress-mediated erythroblast apoptosis and hemolysis
Huiyu Yao, Yue Ma, Lily Jun-shen Huang

Haematologica Aug 2019, haematol.2018.210799; DOI: 10.3324/haematol.2018.210799
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
Samer A. Srour, Amanda Olson, Stefan O. Ciurea, Parth Desai, Qaiser Bashir, Betul Oran, Prithviraj Bose, Rohtesh Mehta, Keyur P. Patel, Naveen Pemmaraju, Naval Daver, Srdan Verstovsek, Richard E. Champlin, Uday R. Popat

Haematologica Jul 2019, haematol.2019.223503; DOI: 10.3324/haematol.2019.223503
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia
Janghee Woo, Dae Ro Choi, Barry E. Storer, Cecilia Yeung, Anna B. Halpern, Rachel B. Salit, Mohamed L. Sorror, David W. Woolston, Tim Monahan, Bart L. Scott, H. Joachim Deeg

Haematologica Jul 2019, haematol.2019.218677; DOI: 10.3324/haematol.2019.218677

More articles from Myeloproliferative Disorders

Pages